Mercury Biopharmaceutical Valuation
Is 6932 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 6932 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 6932's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 6932's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6932?
Other financial metrics that can be useful for relative valuation.
What is 6932's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | NT$5.07b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 4635.1x |
Enterprise Value/EBITDA | -112.2x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 6932's PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3.6x | ||
4166 Orient Pharma | 3.6x | n/a | NT$6.0b |
6838 Formosa Pharmaceuticals | 6.3x | n/a | NT$7.2b |
1752 Nang Kuang Pharmaceutical | 2.4x | n/a | NT$5.5b |
8279 Syngen BiotechLtd | 2x | 11.6% | NT$4.1b |
6932 Mercury Biopharmaceutical | 13.1x | n/a | NT$5.1b |
Price-To-Book vs Peers: 6932 is expensive based on its Price-To-Book Ratio (13.1x) compared to the peer average (3.6x).
Price to Earnings Ratio vs Industry
How does 6932's PE Ratio compare vs other companies in the TW Pharmaceuticals Industry?
Price-To-Book vs Industry: 6932 is expensive based on its Price-To-Book Ratio (13.1x) compared to the TW Pharmaceuticals industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is 6932's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 13.1x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 6932's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.